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Abstract
Background: Hemophagocytic lymphohistocytosis (HLH) is a rare but fatal hyperinflammatory syndrome caused by
uncontrolled proliferation of activated macrophages and T lymphocytes secreting high amounts of inflammatory
cytokines. Genetic defect is a common cause of HLH. HLH is complicated to be diagnosed as there are many
common symptoms with other disorders.
Case presentation: Here we report on an HLH case caused by 1 bp deletion in gene SH2D1A. Patient was a 3-years-old
boy and had fever for more than 8 days. Splenomegaly and hemophagocytosis in bone marrow were observed in
examination. The results of the blood analysis suggested the diagnosis of HLH. Genetic test based on high throughput
amplicon sequencing was then conducted by targeting all six known HLH-causing genes simultaneously. It took only one
single day to accomplish the amplicon sequencing library preparation, sequencing and data analysis. Finally, a novel 1 bp
deletion in gene SH2D1A was discovered. The result was also confirmed by Sanger sequencing. The result of the genetic
test served as a good basis for further diagnosis of HLH.
Conclusion: This is the first case that the disease-causing genetic defect of HLH was quickly determined by high
throughput amplicon sequencing. This diagnosis was also confirmed by Sanger sequencing and cross-validated by blood
analysis and other clinical criteria. This case suggests that genetic test based on amplicon sequencing is a powerful tool
for diagnosis of HLH and other diseases caused by genetic defect.
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Background
Hemophagocytic lymphohistocytosis (HLH) is a poten-
tially fatal disease with severe systemic syndrome, which
is caused by uncontrolled proliferation of activated mac-
rophages and T lymphocytes, and impaired regulation of
the immune system. The first case was reported at 1952
by Farquhar et al., and the mortality rate of HLH ranged
from 22 to 60% [1, 2]. Many reports have revealed that
HLH could affect all age groups, from preterm neonates
to elderly adults [3]. The overall occurrence rate might
be underestimated as it could be diagnosed as other dis-
ease sharing similar symptom [3, 4].
Usually HLH is rapidly fatal unless treated aggressively
[5]. Rapid definitive diagnosis and appropriate treatment
are extremely important for life-saving and improved
prognosis for patients. Established clinical and laboratory
criteria help significantly in accurate clinical diagnosis,
but most of them are time-consuming. Furthermore,
they are not sensitive and specific enough for HLH diag-
nosis, so the results of these tests may be supportive of,
but not diagnostic of, HLH. Therefore, a gene mutation
analysis should be the gold standard for making a defini-
tive diagnosis. To date, a total of 6 causative genes have
been identified, including SH2D1A, PRF1, UNC13D,
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STX11, STXBP2 and XIAP, and a few mutations in these
genes have been reported to be the common cause of
HLH [6–9]. Usually, these genes were checked one by
one to detected mutations. Here, high throughput gen-
etic analysis was conducted to detect mutations in all six
genes simultaneously with amplicon sequencing in a
HLH patient. We identified a novel mutation in gene
SH2D1A, which was also confirmed by Sanger sequen-
cing and this patient was diagnosed as HLH finally. This
indicated that amplicon sequencing was a powerful tool
in diagnosis of genetic disease, especially for cases in-
volved multiple candidate causative genes.
Case presentation
The study was approved by the institute ethics commit-
tee of Key Laboratory of Birthdefects Prevention, Na-
tional Health and Family Planning Commission,
Zhengzhou, China. Informed consent from the parents
was obtained before collecting blood samples. A 3-years-
old boy with HLH was diagnosed based on blood ana-
lysis and genetic detection. The causing mutation was a
homozygous 1 bp deletion (c.92delT) in the first exon of
SH2D1A and this deletion was validated by Sanger se-
quencing. This patient and his parents are all Han Chin-
ese from Henan province of China.
Clinical data
The 3-years-old patient had fever for more than 8 days
with unknown origin when he was admitted to Key La-
boratory of Birthdefects Prevention, National Health and
Family Planning Commission, Zhengzhou, China. He
had taken penicillin for 5 days before admission. On
examination, the temperature was measured to 39.5 °C.
No other respiratory symptoms but tachypnea presented
in physical examination. The central nervous system was
normal. Ultrasound examination revealed splenomegaly.
Blood analysis was conducted at Key Laboratory of
Birthdefects Prevention and hemoglobin was measured
to be 90 g/L. Platelets, Neutrophils and Fibrinogen were
measured to be 22× 109/L, 7.54× 109/L and 3.42 g/L, re-
spectively. Low NK-cell activity (5.05%) and low Plasma
albumin (18.9 g/L) were also observed. The bone mar-
row examination suggested hemophagocytosis without
any evidence of malignancy [Fig. 1]. The results of the
blood analysis and clinical features suggested the diagno-
sis of HLH based on HLH-2004 guidelines [10]. A two-
generation pedigree including the patient and his par-
ents was generated.
Detection of mutation of six genes
Genomic DNA was purified from peripheral blood mono-
nuclear cells PBMC with QIAamp Blood Kit (Qiagen, Hil-
den, Germany) according to the protocol. Multiplexed
primers were designed for 6 disease-causing genes
(SH2D1A, PRF1, UNC13D, STX11, STXBP2 and XIAP)
with Ion AmpliSeq™ Designer (https://www.ampliseq.com)
and a total of 64 exons were covered by these primers, in-
cluding the whole coding regions of these genes and spli-
cing sites for each exon-intron boundaries. Multiplexed
polymerase chain reaction (PCR) amplification was con-
ducted and the PCR product was ligated with adapters,
purified and then sequenced by proton sequencing based
S5XL genetic analyzer (Applied Biosystems®, Life Technolo-
gies, Grand Island, NY, USA) and mutations were analyzed
using VariantCaller V1.0 software embedded in the Torrent
Suited software (Life Technologies). Primer information
could be found in supplementary file [see Additional file 1].
The average base coverage depth for the whole target
regions was 1,515 and more than 97.13% of all sites had
coverage of more than 100-fold, which indicated a good
performance of multiplexed PCR. A total of 19 SNPs (17
heterozygous SNPs and two homozygous SNPs) were
detected in all five genes except XIAP and no insertion
was found in all genes [Table 1]. One homozygous dele-
tion was identified in the first exon of SH2D1A. Among
all 19 SNPs, 11 were known mutations recorded in the
NCBI refSNP database and no known cases have been
reported to be associated with these SNPs. For the
remaining eight novel SNPs, no damage-causing effect
was found by searching literatures and databases, as well
as domain analysis for each protein, including six syn-
onymous mutations and two missense mutations
(c.2599A > G in the 27th exon of gene UNC13D,
c.1576A > G in the 18th exon of gene STXBP2). In sum-
mary, no novel and known SNPs had been proved to be
disease-related mutations.
A novel homozygous 1 bp deletion (c.92delT) was
identified in exon 1 of SH2D1A, which was located on
the X chromosome (at Xq25) [11]. This deletion was
confirmed by Sanger sequencing and also detected in
Fig. 1 The bone marrow examination. Phagocytosis could be clearly
observed in the boon marrow
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the patient’s mother, but not in his father [Fig. 2a].
This indicated that it was not a de novo variation, but
inherited from the mother. Interestingly, this variation
in the mother was found to be heterozygous based on
Sanger sequencing [Fig. 2a]. The deletion resulted in
an introduction of a premature stop codon and pro-
duced a truncated protein (79aa, p.Leu31Argfs*50)
[Fig. 2b]. SH2D1A is a signaling lymphocytic activa-
tion molecule (SLAM)-associated protein (SAP), and
it is one of the known disease-causing genes
associated with immunodeficiency, which led to X-
linked lymphoproliferative disease (XLP) [12]. The
affect of the mutations occurred in SH2D1A typically
manifested in childhood or early adolescence and it
was estimated that it affected 1–3 per million boys
[13]. A lot of mutations in SH2D1A have been identi-
fied and more than 200 cases related with these mu-
tations has been reported [14, 15]. We found three
mutational hotspots in the SH2D1A gene according
to the records in SWISSPROT. The novel 1 bp
Table 1 All variation sites detected by amplicon sequencing
gene-exon
gene-exon





STX11-exon2 c.*70G > A non-coding
region
Homozygous G A 100 740 rs3734228 none disease-
causing




Homozygous G A 100 420 novel none disease-
causing


















































Heterozygous C G 51.8 998 novel none disease-
causing
UNC13D-exon7 c.570-60 T > G intron Heterozygous A C 52.7 995 rs8067076 none disease-
causing
UNC13D-exon1 c.117 + 30G > A intron Heterozygous C T 48.2 842 rs3744011 none disease-
causing
STXBP2-exon2 c.38-7C > T intron Heterozygous C T 59.5 79 rs8104339 none disease-
causing
STXBP2-exon15 c.1356 + 18A > G intron Heterozygous A G 47.2 998 rs889187 none disease-
causing
STXBP2-exon15 c.1356 + 77A > G intron Heterozygous A G 46.9 997 rs710951 none disease-
causing




Heterozygous T C 52.9 357 novel none disease-
causing
STXBP2-exon18 c.1576A > G
p.Ile526Val
missense Heterozygous A G 46.5 185 novel none disease-
causing






Homozygous T - 100 864 novel disease-causing
a Coverage means the overall depth of this site by amplicon sequencing reads
b If a known variant was detected for the targeted gene,its accession No kept in NCBI was listed, or we marked it as novel
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deletion (c.92delT) presented here was located in the
first one of these mutational hotspots.
Discussion
In this case, two other possible diseases have been noted
considering that SH2D1A mutation could involve in
rheumatoid arthritis (RA) [16] and systemic lupus ery-
thematosus [17], but both of these diseases were ex-
cluded. Firstly, splenomegaly and Hemophagocytosis in
bone marrow were observed in examination, and all
blood analysis showed that some key indexes fitted in
with the diagnosis of HLH based on HLH-2004 guide-
lines, which has been revised at 2007. If the child had
RA, the temperature will not be as high as 39.5 °C, but
just low-grade fever. And it should not be systemic lupus
erythematosus, because no obvious symptoms could be
found in physical examination. The central nervous sys-
tem was also normal. Together with the identification of
1 bp deletion in exon of SH2D1A, a diagnosis of HLH
could be accepted. However, it is interesting to note
that the gene SH2D1A is located on the X chromo-
some [11] and Sanger sequencing revealed that the
mutation was heterozygous in the mother, which
might explain why his mother had no obvious symp-
toms of HLH. This also indicated that the case pre-
sented here was X-linked genetic disease, especially
considering the incidence of the patient. As soon as
sequencing result was acquired and HLH diagnosis
was confirmed, the patient received full course of
dexamethasone combining with VP-16 chemotherapy,
according to the guideline of HLH-2004 protocol
[10]. The clinical manifestation quickly stabilized and
currently he is under treatment for further HSCT
procedure.
SH2D1A encodes the signaling lymphocytic activation
molecule (SLAM)-associated protein (SAP), which inter-
acts with members of the CD2 subset of the Ig super-
family of cell-surface receptors [12]. It has been reported
Fig. 2 Mutations in the gene SH2D1A. a Sanger sequencing results of the 3-years-old child (underside), his father (top left) and his mother (top right).
Mutation position is marked with red arrow. The results show heterozygosity for this mutation in his mother, but wild type sequences in his father. As
indicated, deleted nucleotide caused a frameshift in the corresponding sequence. b) Mutations recorded in SWISSPROT. All mutations are marked in blue
and each mutational hotspot is indicated by black box. Almost all the mutations located in these three regions have been reported to be disease-causing
defects. The novel deletion detected in this study is marked with red arrow and the premature stop codon is marked with purple arrow. “VAR_048***” is
the accession No in SWISSPROT, “ND” represents for “Not detected”, “+” indicates that the mutation could reduce protein stability or interaction with other
protein, “++” indicates a significant reduction and “N” indicates totally abolished interaction with SLAMF1. “-“means no data available
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that there are three putative acting mechanisms that could
cause XLP due to mutation in SH2D1A, including reduced
gross expression, reduced ability binding to SLAM family
receptors and inability to activate signal transduction
downstream of the SLAM receptor–SAP complex effi-
ciently [18]. In the present case, it is believed that no func-
tional protein was generated due to deletion of 92th base
(T), which could lead to functional defects in natural killer
(NK) cells. NK cells are required for clearance of viral in-
fection as well as regulation and termination of the in-
flammatory response [19]. Phagocytes, neutrophils and
NK cells constitute the innate immune system and persist-
ent antigen exposure will keep them active. These acti-
vated cells released proimflammatory cytokines such as
TNF-α, IL-1 and IL-6, which could cause fever, hyperferri-
tinemia and other symptoms.
HLH occurs predominantly in infants and very young
children. Based on the mechanism of morbidity, HLH can
either be genetic, or acquired due to viral infections, malig-
nancies or rheumatic diseases. According to classification
of histiocytic disorders, HLH is subdivided into familial
HLH (FHLH) and secondary HLH (sHLH) [2]. Based on
genetic etiology, FHLH has been subcategorized into 5 sub-
types, i.e., FHLH-1 to FHLH-5 [20]. However, these disor-
ders may be difficult to be distinguished from each other
clinically. For example, the clinical symptoms of familial
HLH usually become evident within the first 2 months of
life, but most clinicians cannot distinguish FHL from other
disorders if the patient is the first child or in the absence of
affected siblings.
A set of clinical and laboratory criteria have been
established for accurate diagnose of HLH [10], such
as prolonged high-grade fever, progressive cytope-
nias, hepatosplenomegaly with liver dysfunction, skin
rash, coagulopathy and variable neurologic symp-
toms, and these criteria have been widely used in
clinical practice. The pathologic findings of activated
macrophages, engulfing erythrocytes, leukocytes,
platelets and their precursor cells were also import-
ant for diagnosis of HLH. However, not all HLH
cases present these clinical manifestations in the ini-
tial stage [21], and the organs involved may be dif-
ferent [22]. Especially, it is has been reported that
HLH may also commonly occurred in a setting of
rheumatologic illness [23].
In practice, analysis of bone marrow aspirate is com-
monly used for HLH diagnosis, which only has a sensitiv-
ity of 60% [24]. Therefore, a negative bone marrow
analysis result should not completely rule out HLH. A set
of other rapid diagnostic tests have been proposed to aid
the diagnosis of HLH, including Ferritin, soluble IL-2 re-
ceptor, IFN-g, IL-10 and other proinflammatory cytokines
[10, 25, 26]. All these indices have been reported to be
useful in diagnosing HLH. Novel methods have also been
developed for the early and rapid detection of patients. For
example, flow cytometry assay has been used to evaluate the
expression of lymphoid SAP (XLP1), perforin and XIAP
(XLP2) [27], and it could also detect revertants and somatic
mutations [28]. It has to be noted that all these criteria and
methods are proposed based on physiological indices, not
genetic, and they have limited sensitivity and specificity for
HLH. On the other side, screening of mutations in all these
6 causative genes are generally conducted by Sanger sequen-
cing, and constrained by its low throughput. Now high
throughput sequencing is cost-effective and time-effective for
genetic testing, and it could detect all target loci simultan-
eously in 1 day, even most proportion of whole genome if
necessary. Together with highly multiplexed PCR technol-
ogy, it could identify all kinds of variants with high accurate
by covered the target region (i.e., causative genes) with a
proper depth. This may help to reduce the time consumed
by differential diagnosis and make the definitive diagnosis
rapidly. This is extremely important for life-saving and get-
ting improved prognosis by giving patients appropriate treat-
ment as soon as possible. In order to prevent misdiagnosis
and give as much information as possible for clinicians, it will
be helpful and necessary to do this genetic analysis immedi-
ately with amplicon sequencing after child is born.
Conclusion
In summary, 6 HLH-related genes were tested at once
in a suspected HLH patient and a novel homozygous
1 bp deletion (c.92delT) in exon 1 of SH2D1A was
indentified. The diagnosis of HLH was further con-
firmed by this result. Most HLH occurred in child-
hood and the survival rate is very poor, even with
treatment [29]. Rapid definitive diagnosis and appro-
priate treatment are extremely important for life-
saving and prognosis-improving. This indicated that
amplicon sequencing is necessary for rapid and accur-
ate screening of mutations in the diagnosis of genetic
disease, especially those clinically indistinguishable
disorders. Other methods based on DNA and proteins
analysis have been reported for the detection of
SH2D1A mutation [28, 30], but none could be used
to detect all possible genes simultaneously and rap-
idly. Ultimately, this case proposed a novel method to
identify HLH-related mutations, and improve the un-
derstanding of their roles during the regulation of
host antiviral immune responses. It will also facilitate
development of novel therapies for these rare but
devastating disorders.
Additional file
Additional file 1 Table S1: List of primers that were used for amplicon
sequencing. (XLSX 19 kb)
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